{
    "DATE": " 5-MAR-1987 12:50:39.09",
    "TOPICS": [
        "acq"
    ],
    "PLACES": [
        "usa"
    ],
    "NEWID": "2271",
    "TEXT": {
        "TITLE": "KODAK <EK> BUYS STAKE IN ENZON <ENZN>",
        "DATELINE": "    ROCHESTER, N.Y., March 5 - ",
        "BODY": "Eastman Kodak Co said it has\nacquired an 18.7 pct equity interest in Enzon Inc, a\npharmaceutical company specializing in protein therapy.\n    Kodak said it secured worldwide marketing rights for three\nof Enzon's PEG enzymes used in the treatment of oxygen toxicity\ndisorders, hyperuricemia and gout.\n    The company said it acquired two mln Enzon shares for 15\nmln dlrs, with loans to Enzon of two mln dlrs and interest of\n30,000 dlrs credited against the purchase price.\n    Kodak said the drugs covered by the marketing rights are in\ninitial stages of the U.S. Food and Drug Administration\napproval process.  It said the investment should provide the\nnecessary capital to complete the FDA review process and\nprovide a marketing outlet for the drugs.\n    The drugs are PEG-superoxide disdmutase and PEG-catalase,\nfor use against oxygen toxicity disorders that cause the\noften-fatal tissue damage associated with severe burns, organ\ntransplants, heart attacks and trauma, and PEG-uricase, for\ntreatment of gout and other conditions caused by the buildup of\nhigh levels of uric acid in the body.\n Reuter\n\u0003"
    },
    "PEOPLE": [
        "duisenberg",
        "ruding"
    ],
    "ORGS": [
        "ec"
    ]
}